摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-(5-(2-(3-methylpiperidin-1-yl)-4-(trifluoromethyl)oxazole-5-carboxamido)pyridin-2-yl)piperazine-1-carboxamido)benzoic acid | 1228003-42-6

中文名称
——
中文别名
——
英文名称
2-(4-(5-(2-(3-methylpiperidin-1-yl)-4-(trifluoromethyl)oxazole-5-carboxamido)pyridin-2-yl)piperazine-1-carboxamido)benzoic acid
英文别名
2-[[4-[5-[[2-(3-Methylpiperidin-1-yl)-4-(trifluoromethyl)-1,3-oxazole-5-carbonyl]amino]pyridin-2-yl]piperazine-1-carbonyl]amino]benzoic acid
2-(4-(5-(2-(3-methylpiperidin-1-yl)-4-(trifluoromethyl)oxazole-5-carboxamido)pyridin-2-yl)piperazine-1-carboxamido)benzoic acid化学式
CAS
1228003-42-6
化学式
C28H30F3N7O5
mdl
——
分子量
601.585
InChiKey
RARWWMWCVYXRHA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    43
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    144
  • 氢给体数:
    3
  • 氢受体数:
    12

文献信息

  • INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
    申请人:Ting Pauline C.
    公开号:US20110224136A1
    公开(公告)日:2011-09-15
    The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below.
    本发明涉及新型杂环化合物作为二酰基甘油酰基转移酶(“DGAT”)抑制剂,包含这些杂环化合物的制药组合物以及使用这些化合物治疗或预防心血管疾病、代谢紊乱、肥胖或肥胖相关的疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损。本发明的一种示例化合物如下所示。
  • [EN] INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE<br/>[FR] INHIBITEURS DE DIACYLGLYCÉROL ACYLTRANSFÉRASE
    申请人:SCHERING CORP
    公开号:WO2010059606A2
    公开(公告)日:2010-05-27
    The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ("DGAT") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below.
查看更多